ZS Launches ZAIDYN™ Clinical Development, Expanding Its Digital Life Sciences Platform
17.6.2022 16:45:00 EEST | Business Wire | Press release
Global management consulting and technology firm ZS has announced the launch of ZAIDYN Clinical Development. The offering is the latest expansion of the platform ZAIDYN by ZS, designed to empower life sciences companies to digitally transform and scale customer engagement, field performance, analytics and—now—clinical development design and planning.
“Today, we’re announcing the launch of ZAIDYN Clinical Development, expanding on more than 35 years of software expertise,” said Sanjay Joshi, managing principal and platform lead for ZS. “With ZAIDYN, life sciences organizations can connect their global teams, products, processes, applications, algorithms and data assets for powerful insights to shape clinical research and accelerate clinical development timelines. Our platform works with existing IT systems to fuel efficiency and connectivity, reduce costs and empower life sciences companies of all sizes to innovate, scale and grow as the global healthcare ecosystem evolves.”
ZAIDYN Clinical Development harnesses the power of a self-learning network, AI-driven insights and algorithms to create a fluid, fast, frictionless trial experience for business users, site investigators and patients. With our products, companies have the power to:
- Drive innovation and decision-making throughout the clinical development process with insightful, dynamic reporting and analytics for clinical teams and a high-level view of clinical trial operations for leaders
- Optimize clinical study planning and protocol design using AI and predictive insights that reflect the experiences and perspectives of participants and patients
- Empower teams to test and model site and enrollment scenarios to find ways to make studies more inclusive and engaging, lift participant burden, limit amendments and accelerate trial efficiency
- Create an expanding universe of industry and historical clinical trial data, real-world data, site criteria and patient survey insights
- Raise the bar for clinical research with products built on Amazon Web Services (AWS) that apply the latest clinical data standards and fuel connectivity throughout upstream and downstream systems
More than 130 companies already use ZS’s products to drive business decisions. Now, these companies can combine the clinical expertise of ZS consulting with the latest features of ZAIDYN Clinical Development to break down business and clinical silos and empower teams to work together more efficiently.
“ZAIDYN Clinical Development will help our clients navigate the large-scale, disruptive changes we see happening across our industry—and those on the horizon as AI and machine learning transform clinical research and development (R&D),” said Aaron Mitchell, ZS’s global R&D excellence practice leader. “Smarter platforms for life sciences can help us improve clinical trial diversity, bring life-saving therapies to patients faster, and unlock patterns and breakthroughs that will transform the future of clinical research. It’s all about using insights from data more effectively to drive more inclusive studies and better patient outcomes.”
“With the support of ZS and the ZAIDYN platform, we’re accelerating the transformation we initiated three years ago,” reflected Cynthia Deparis, program manager at Sanofi. “The platform is helping us take a data-driven approach to identifying the best countries and sites for clinical studies. It’s helped us integrate and expand the universe of clinical operational trial data so we can target sites and countries that help us deliver on our development portfolio and think through various strategic parameters like the competitive landscape, our peers’ activity, historical knowledge about sites and feedback from outreached sites. With these insights and the ability to model different scenarios, we can continue to optimize recruitment and enhance the accuracy of our projections, setting our clinical trial development on a continuous improvement cycle.”
About ZS
ZS is a management consulting and technology firm focused on transforming global healthcare and beyond. We leverage our leading-edge analytics, plus the power of data, science and products to help our clients make more intelligent decisions, deliver innovative solutions and improve outcomes for all. Founded in 1983, ZS has more than 12,000 employees in 35 offices worldwide. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220617005012/en/
Contact information
Quintin Maidment; ZS@theblissgrp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 20:48:00 EEST | Press release
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr
Coulson Aviation Canada Acquires 10 Former RCAF Hercules, Doubling C-130H Fleet7.8.2026 20:16:00 EEST | Press release
Coulson Aviation Canada, the Canadian division of Coulson Aviation, has acquired 10 former Royal Canadian Air Force CC-130H Hercules aircraft from the Government of Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807019094/en/ Britton Coulson, left, and Wayne Coulson stand in front of one of 10 former Royal Canadian Air Force CC-130H Hercules aircraft recently acquired by Coulson Aviation from the Government of Canada. At right is a Coulson C-130H outfitted for aerial firefighting with the company’s proprietary RADS-XXL retardant delivery system, capable of carrying up to 4,000 U.S. gallons, or more than 15,000 litres, of water or fire retardant. The acquisition doubles Coulson’s global C-130H fleet to 20 aircraft, expanding its capacity to build the world’s largest C-130 airtanker fleet. The acquisition doubles Coulson’s global C-130H fleet from 10 aircraft to 20 and gives its Canadian division the scale to build
Energy Vault Announces Strategic Agreement to Deploy 1.25 GW of Integrated Power Infrastructure for Hyperscaler AI Data Center with Leading Power Generation EPC Deploying Caterpillar Gensets7.8.2026 19:16:00 EEST | Press release
Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a global leader in sustainable energy infrastructure, today announced the execution of a strategic commercial agreement under which Energy Vault will supply battery energy storage systems ("BESS"), grid-forming power conversion systems and AI infrastructure controlsoftware to support an initial deployment totaling 1.25 gigawatts ("GW") of integrated power infrastructure for hyperscaler AI data centers. The agreement establishes a repeatable AI power infrastructure platform that combines dispatchable power generation, intelligent battery energy storage, grid-forming inverter systems, advanced AI infrastructure controls software and turnkey EPC and plant integration into a single integrated solution designed specifically for hyperscaler AI data centers and high-performance computing campuses. The companies will jointly deploy fully integrated, off-grid power systems capable of bringing AI compute capacity online significantly fas
SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 11:52:00 EEST | Press release
SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously communicated. No future exceptional cash proceeds will be used to fund the project. Since the signing of the IRIS² Concession Contract in
Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 08:10:00 EEST | Press release
2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026 Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment eff
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom